Viewing Study NCT03854903

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:16 PM
Ignite Modification Date: 2025-12-30 @ 2:07 PM
Study NCT ID: NCT03854903
Status: COMPLETED
Last Update Posted: 2025-02-06
First Post: 2019-02-21
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
Sponsor: Georgetown University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Breast Cancer View
None Human Epidermal Growth Factor 2 Negative Carcinoma of Breast View
None Hormone Receptor Positive Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None breast cancer View
None HR+ View
None HER2- View
None HR positive View
None HER2 negative View
None metastatic View
None aromatase inhibitor View
None CDK4/6 inhibitor View
None palbociclib View
None bosutinib View
None fulvestrant View
None Faslodex View